search
Back to results

Exercise on microRNA in Osteoarthritis

Primary Purpose

Osteoarthritis, Knee, Epigenetic Disorder, Quality of Life

Status
Completed
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
Exercise Programme
Experiments
Sponsored by
Saglik Bilimleri Universitesi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis, Knee focused on measuring Osteoarthritis, Epigenetic Disorder, Quality of Life, Depression, Pain

Eligibility Criteria

38 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Having Kellgren-Lawrence grade 2 or grade 3 knee OA Body mass index (BMI) between 20-35. Exclusion Criteria: Rheumatoid Arthritis, Having knee replacement surgery, Intra-articular injection in the last six months, Usage of opioid analgesics or corticosteroids, Being under severe pain (VAS>7), Pregnancy, Having cardiovascular disease, Stroke and chronic obstructive pulmonary disease (COPD).

Sites / Locations

  • Bakırköy Dr. Sadi Konuk Training and Hospital Research Hospital, Physical Medicine and Rehabilitation

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Exercise Group

Arm Description

A total of 30 knee OA patients and 30 age/sex-matched healthy volunteers were included in the exercise and control groups. Exercises were performed twice a week under supervision and once a week as home program for eight weeks. Before and after exercise treatment, peripheral venous blood samples were taken from both groups. miRNA-146a, miRNA-155, miRNA-221-3p and miRNA-145 gene expressions were studied with the Real-time PCR method. miRNA-146a, miRNA-155, and miRNA-221-3p, miRNA-145 gene expressions were studied with the Real-time PCR method. The pain was evaluated with the Numeric Rating Scale (NRS), functional status with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), depression level with the Beck Depression Inventory (BDI), and quality of life with Short Form-36 (SF-36).

Outcomes

Primary Outcome Measures

Pre-Treatment Gene Expressions of microRNA for Treatment Group
By examining the expression level of RNA, U6 small nuclear 1 (human) as a control gene, it is decided whether the expression levels of microRNAs are expressed up or down.
Post-Treatment Gene Expressions of microRNA for Treatment Group
By examining the expression level of RNA, U6 small nuclear 1 (human) as a control gene, it is decided whether the expression levels of microRNAs are expressed up or down.
Gene Expressions of microRNA for Healthy Control Group
By examining the expression level of RNA, U6 small nuclear 1 (human) as a control gene, it is decided whether the expression levels of microRNAs are expressed up or down.
Pre-Treatment Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for Treatment Group
WOMAC was used to evaluate functional status. There are a total of 24 questions on pain, morning stiffness and physical function. 0 points means 'not at all', 1 point means 'mild', 2 points 'moderate', 3 points 'severe', 4 points 'very severe'. The total score is between 0 and 100, and a low score means that the individual is in good health.
Post-Treatment Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for Treatment Group
WOMAC was used to evaluate functional status. There are a total of 24 questions on pain, morning stiffness and physical function. 0 points means 'not at all', 1 point means 'mild', 2 points 'moderate', 3 points 'severe', 4 points 'very severe'. The total score is between 0 and 100, and a low score means that the individual is in good health.

Secondary Outcome Measures

Short Form-36 (SF-36)
SF-36 was used to evaluate quality of life. This questionnaire consists of eight subsections. Scoring is made between 0-100 for each of the subsections. Higher scores indicate better function and well-being.
Beck Depression Inventory (BDI)
BDI was used to evaluate depression level. The test consists of 20 questions and each question includes 0, 1, 2, 3 points. takes. At the end of the test; The scores marked by the patient for each question are summed up and the depression status is evaluated according to the score. The higher the score, the higher the level of depression.
Numeric Rating Scale (NRS)
NRS was used to pain level. A score of 0 means 'no pain' and a score of 10 means 'unbearable pain'.

Full Information

First Posted
May 6, 2023
Last Updated
June 2, 2023
Sponsor
Saglik Bilimleri Universitesi
search

1. Study Identification

Unique Protocol Identification Number
NCT05869630
Brief Title
Exercise on microRNA in Osteoarthritis
Official Title
Investigation Into the Effects of Exercise on microRNA Expressions in Patients With Knee Osteoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
August 1, 2018 (Actual)
Primary Completion Date
September 11, 2019 (Actual)
Study Completion Date
June 17, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Saglik Bilimleri Universitesi

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The present study is a prospective cohort study. This study will be conducted to determine the change in miRNA levels with exercise in knee Osteoarthritis (OA) patients. The main questions that the study aims to answer are: Question 1: Does exercise therapy affect microrna expressions in patients with knee osteoarthritis? Question 2: Does exercise therapy affect quality of life, pain, functional status and depression level in patients with knee osteoarthritis? Participants; demographic information such as age, height, weight will be questioned. Exercises will performed twice a week under supervision and once a week as home program for eight weeks. Before and after exercise treatment, peripheral venous blood samples will taken from both groups. miRNA-146a, miRNA-155, miRNA-221-3p and miRNA-145 gene expressions will studied with the real-time PCR (polymerase chain reaction) method. miRNA-146a, miRNA-155, and miRNA-221-3p, miRNA-145 gene expressions will studied with the Real-time PCR method. The pain will evaluated with the Numeric Rating Scale (NRS), functional status with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), depression level with the Beck Depression Inventory (BDI), and quality of life with Short Form-36 (SF-36).
Detailed Description
Osteoarthritis is a degenerative disease causing joint pain, stiffness, and limitation of motion with loss of cartilage, osteophyte development, subchondral sclerosis, changes in the joint capsule and synovial membrane as a result of the disruption of genetic, biomechanical, and biochemical balances. Pharmacological treatments of osteoarthritis include simple analgesics, non-steroidal anti-inflammatory drugs, opioids and topical analgesics. Patient education, self-management programs, exercise, weight loss, assistive devices and lifestyle changes are non-pharmacological treatment methods.Exercise is one of the basic elements of the treatment modality. The purpose of the exercise; to relieve symptoms and improve muscle strength around joints. It is aimed to increase the quality of life with the adaptation of individuals to exercise. miRNA, one of the small non-coding RNA subunits, is responsible for the modulation of protein-coding genes as a result of post-transcriptional repression. miRNA play an active role in many biological events such as cellular differentiation, apoptosis, proliferation, erythropoiesis, fibrosis and angiogenesis. Due to the role of miRNAs in normal development and diseases, it is thought that they will be a new biomarker for therapeutic purposes in the future. It was found that miRNAs play a key role in physiological conditions e.g. skeletal muscle hypertrophy, mitochondrial biogenesis, vascular angiogenesis, and metabolic events when combined with exercise. The identification of miRNAs that change in circulation with exercise is important in terms of providing new data on the physiological adaptation of exercise. In recent years, a large number of miRNAs have been identified in osteoarthritic tissues, which is important in terms of the regulation of gene expressions related to the pathogenesis of OA. OA-specific miRNA expressions is necessary for early diagnosis and treatment of OA as well as for monitoring the progression of the disease. It has been reported that miRNA-146a is intensely expressed in OA tissue and its expression is induced by inflammatory cytokines. MiRNA-145 is associated with chondrocyte homeostasis and is thought to be involved in the degradation of the extracellular matrix. MiRNA-155 is a miRNA that has a role in the development and regulation of innate and acquired immunity, and its expression is increased in tissues with OA compared to healthy tissue. It has an important role in hematopoiesis. MiRNA-221-3p was found to be associated with chondrocyte proliferation, gene expression, matrix degradation and apoptosis. In this study it was aimed to determine the changes in miRNA levels of knee OA patients with exercise.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee, Epigenetic Disorder, Quality of Life, Depression, Pain
Keywords
Osteoarthritis, Epigenetic Disorder, Quality of Life, Depression, Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Prospective Cohort Study
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exercise Group
Arm Type
Experimental
Arm Description
A total of 30 knee OA patients and 30 age/sex-matched healthy volunteers were included in the exercise and control groups. Exercises were performed twice a week under supervision and once a week as home program for eight weeks. Before and after exercise treatment, peripheral venous blood samples were taken from both groups. miRNA-146a, miRNA-155, miRNA-221-3p and miRNA-145 gene expressions were studied with the Real-time PCR method. miRNA-146a, miRNA-155, and miRNA-221-3p, miRNA-145 gene expressions were studied with the Real-time PCR method. The pain was evaluated with the Numeric Rating Scale (NRS), functional status with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), depression level with the Beck Depression Inventory (BDI), and quality of life with Short Form-36 (SF-36).
Intervention Type
Other
Intervention Name(s)
Exercise Programme
Intervention Description
All patients were informed about knee OA, joint protection principles, and the exercise effects on knee OA before treatment. The exercises were supervised by a physiotherapist for 30 minutes twice a week and once a week as a home program. The exercise program consisted of a warm-up, strengthening knee extensors and lower extremity stretching exercises. Firstly, quadriceps isometric and adductor isometric (roll tightening) exercises, hamstring stretching, quadriceps stretching, and gastrocnemius stretching were applied. Then, hip flexion-extension-abduction-adduction, and knee extension while sitting were applied with exercise bands. Strengthening exercises were composed of three sets with 10 repetitions. Stretching exercises were performed 10 repetitions for 10 seconds.
Intervention Type
Other
Intervention Name(s)
Experiments
Intervention Description
The total RNA was isolated from peripheral blood samples taken from patients and the control group by applying the protocol of the manufacturer (LucigenMasterPure™ Complete DNA and RNA Purification Kit, USA). The total RNA was isolated in three steps: Lysis stage of the whole blood samples, precipitation of nucleic acids and precipitation of total RNA. The purity and concentration of the isolated total RNA samples were measured with the spectrophotometer (Thermo Fischer) device. The samples were stored at -80°C until the next step. To determine the microRNA expression levels; firstly, conjugate DNA (cDNA) was synthesized from total RNA samples according to the manufacturer's protocol. Whether the desired region reproduced in the reaction and whether there were primer dimers were checked by adding a melting curve step. In addition, blood samples of 30 age-sex matched healthy volunteers were compared.
Primary Outcome Measure Information:
Title
Pre-Treatment Gene Expressions of microRNA for Treatment Group
Description
By examining the expression level of RNA, U6 small nuclear 1 (human) as a control gene, it is decided whether the expression levels of microRNAs are expressed up or down.
Time Frame
Baseline
Title
Post-Treatment Gene Expressions of microRNA for Treatment Group
Description
By examining the expression level of RNA, U6 small nuclear 1 (human) as a control gene, it is decided whether the expression levels of microRNAs are expressed up or down.
Time Frame
Through study completion, an average of 2 months.
Title
Gene Expressions of microRNA for Healthy Control Group
Description
By examining the expression level of RNA, U6 small nuclear 1 (human) as a control gene, it is decided whether the expression levels of microRNAs are expressed up or down.
Time Frame
Baseline
Title
Pre-Treatment Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for Treatment Group
Description
WOMAC was used to evaluate functional status. There are a total of 24 questions on pain, morning stiffness and physical function. 0 points means 'not at all', 1 point means 'mild', 2 points 'moderate', 3 points 'severe', 4 points 'very severe'. The total score is between 0 and 100, and a low score means that the individual is in good health.
Time Frame
Baseline
Title
Post-Treatment Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for Treatment Group
Description
WOMAC was used to evaluate functional status. There are a total of 24 questions on pain, morning stiffness and physical function. 0 points means 'not at all', 1 point means 'mild', 2 points 'moderate', 3 points 'severe', 4 points 'very severe'. The total score is between 0 and 100, and a low score means that the individual is in good health.
Time Frame
At the beginning of the intervention and through study completion, an average of 2 month
Secondary Outcome Measure Information:
Title
Short Form-36 (SF-36)
Description
SF-36 was used to evaluate quality of life. This questionnaire consists of eight subsections. Scoring is made between 0-100 for each of the subsections. Higher scores indicate better function and well-being.
Time Frame
At the beginning of the intervention and through study completion, an average of 2 month
Title
Beck Depression Inventory (BDI)
Description
BDI was used to evaluate depression level. The test consists of 20 questions and each question includes 0, 1, 2, 3 points. takes. At the end of the test; The scores marked by the patient for each question are summed up and the depression status is evaluated according to the score. The higher the score, the higher the level of depression.
Time Frame
At the beginning of the intervention and through study completion, an average of 2 month
Title
Numeric Rating Scale (NRS)
Description
NRS was used to pain level. A score of 0 means 'no pain' and a score of 10 means 'unbearable pain'.
Time Frame
At the beginning of the intervention and through study completion, an average of 2 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
38 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Having Kellgren-Lawrence grade 2 or grade 3 knee OA Body mass index (BMI) between 20-35. Exclusion Criteria: Rheumatoid Arthritis, Having knee replacement surgery, Intra-articular injection in the last six months, Usage of opioid analgesics or corticosteroids, Being under severe pain (VAS>7), Pregnancy, Having cardiovascular disease, Stroke and chronic obstructive pulmonary disease (COPD).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fulya Senem KARAAHMETOĞLU, M.Sc
Organizational Affiliation
Saglik Bilimleri Universitesi
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Zeynep Betül ÖZCAN, M.Sc
Organizational Affiliation
Saglik Bilimleri Universitesi
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Meltem VURAL, Prof. Dr.
Organizational Affiliation
Istanbul Bakırköy Dr.Sadi Konuk Training and Research Hospita
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Işıl ÜSTÜN, Dr.
Organizational Affiliation
Istanbul Bakırköy Dr.Sadi Konuk Training and Research Hospita
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Alev KURAL, Prof. Dr.
Organizational Affiliation
Istanbul Bakırköy Dr.Sadi Konuk Training and Research Hospita
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Sibel KURAŞ, M. Sc.
Organizational Affiliation
Saglik Bilimleri Universitesi
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Bekir ERDOĞAN, M.Sc
Organizational Affiliation
Saglik Bilimleri Universitesi
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Halime Hanım PENÇE, Assoc. Prof.
Organizational Affiliation
Saglik Bilimleri Universitesi
Official's Role
Study Director
Facility Information:
Facility Name
Bakırköy Dr. Sadi Konuk Training and Hospital Research Hospital, Physical Medicine and Rehabilitation
City
Istanbul
Country
Turkey

12. IPD Sharing Statement

Learn more about this trial

Exercise on microRNA in Osteoarthritis

We'll reach out to this number within 24 hrs